COVID-19 Incidence and Outcomes in a Home Dialysis Unit in Madrid (Spain) at the Height of the Pandemic
Overview
Authors
Affiliations
Introduction: The 2019 coronavirus (COVID-19) is a viral infection caused by a new coronavirus that is affecting the entire world. There have been studies of patients on in-center hemodialysis (HD), but home dialysis population data are scarce. Our objective is to study the incidence and course of COVID-19 in a home dialysis unit (HDU) at the height of the pandemic.
Methods: an observational, retrospective study enrolling all patients diagnosed with COVID-19 from the HDU of Hospital Universitario La Paz [La Paz University Hospital] (Madrid, Spain) between March 10 and May 15, 2020. We collected clinical data from the HDU (57 patients on peritoneal dialysis [PD] and 22 patients on home hemodialysis [HHD]) and compared the clinical characteristics and course of patients with and without COVID-19 infection.
Results: twelve patients were diagnosed with COVID-19 (9 PD; 3 HHD). There were no statistically significant differences in terms of clinical characteristics between patients with COVID-19 and the rest of the unit. The mean age was 62 ± 18.5 years; most were men (75%). All patients but one required hospitalization. Ten patients (83%) were discharged following a mean of 16.4 ± 9.7 days of hospitalization. Two patients were diagnosed while hospitalised for other conditions, and these were the only patients who died. Those who died were older than those who survived.
Conclusion: The incidence of COVID-19 in our HDU in Madrid at the height of the pandemic was high, especially in patients on PD. No potential benefit for preventing the infection in patients on home dialysis was observed. Advanced age and nosocomial transmission were the main factors linked to a worse prognosis.
Iorga C, Iorga C, Andreiana I, Stancu S, Bengulescu I, Constantin T Life (Basel). 2024; 14(7).
PMID: 39063560 PMC: 11277704. DOI: 10.3390/life14070805.
[Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines].
Sanchez-Alvarez E, Quiroga B, de Sequera P Nefrologia. 2024; 41(4):412-416.
PMID: 38620386 PMC: 7775792. DOI: 10.1016/j.nefro.2020.12.002.
COVID-19 incidence and outcomes among patients with kidney replacement therapy.
Changsirikulchai S, Sangthawan P, Janma J, Rajborirug S, Ingviya T Kidney Res Clin Pract. 2023; 42(5):649-659.
PMID: 37813525 PMC: 10565457. DOI: 10.23876/j.krcp.22.240.
Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.
Sanchez-Alvarez E, Quiroga B, de Sequera P Nefrologia (Engl Ed). 2021; 41(4):412-416.
PMID: 34561208 PMC: 8455244. DOI: 10.1016/j.nefroe.2021.09.001.
Initial Effects of COVID-19 on Patients with ESKD.
Weinhandl E, Wetmore J, Peng Y, Liu J, Gilbertson D, Johansen K J Am Soc Nephrol. 2021; 32(6):1444-1453.
PMID: 33833076 PMC: 8259631. DOI: 10.1681/ASN.2021010009.